Teva Pins Long-Term Hopes In MS On Return Of Laquinimod
This article was originally published in Scrip
Executive Summary
After missing out on the initial wave of oral multiple sclerosis drugs, Teva Pharmaceutical Industries Ltd. still has its eye on the oral immunomodulator laquinimod as a future pillar for the firm in multiple sclerosis. Teva is hoping for a launch in 2018 after a third and final Phase III trial reads out in 2017.
You may also be interested in...
Sanofi Paid $14.6bn In Rebates In 2020; Net Prices Were Down
The company released an annual pricing report, showing that Sanofi's US average net prices declined for the fifth year in a row.
Biohaven Shoots For Oral CGRP Leadership As Nurtec ODT Gains Momentum
The firm’s acute migraine treatment Nurtec ODT generated $65m in 2020 after launching a year ago. Biohaven aims for Nurtec to become the leader in what could be a $4bn-$5bn category in the US.
Merck & Co. Buys Pandion, Building Out Capability In Autoimmune Disease
Merck & Co. reached a deal to acquire the developer of targeted immune modulators for $1.85bn. Pandion CEO Kakkar talked to Scrip about the acquisition.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: